Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed. | Novartis
The Pharma Data
APRIL 26, 2021
COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. billion declined, mainly due to the USD 650 million upfront payment to in-license tislelizumab from BeiGene. Adakveo sales reached USD 37 million. Free cash flow¹ of USD 1.6
Let's personalize your content